Legal deadline looms for Capricor Therapeutics investors as class action lawsuit seeks lead plaintiffs for securities fraud claims
Executive summary: Rosen Law Firm is notifying Capricor Therapeutics investors with losses exceeding $100,000 about the opportunity to lead an ongoing securities fraud class action lawsuit. The litigation follows a massive decline in stock value, potentially impacting the company's capital access and legal liabilities.
Who is involved: Capricor Therapeutics (NASDAQ: CAPR), Rosen Law Firm, and investors who purchased securities between Dec 17, 2025, and July 26, 2026.
Likely next: Submission of lead plaintiff applications by interested investors ahead of the September 28, 2026 deadline.
Rosen Law Firm has issued a reminder to shareholders of Capricor Therapeutics (NASDAQ: CAPR) regarding a critical deadline to participate in a securities fraud lawsuit. The legal action targets a specific class period between December 2025 and July 2026, following significant stock volatility. This development highlights the ongoing litigation risk facing the biotech company as multiple law firms compete for lead plaintiff status.
What's next — scenarios
Base Case: Lead plaintiff appointment (60%)
A large investor is appointed to lead the litigation, increasing the scale of the class action.
- Successful filing of motions by major law firms by Sept 28
Downside: Settlement proceedings begin (30%)
The company faces significant cash outflows to settle claims and avoid prolonged trial.
- Discovery phase reveals evidence of material misstatements regarding clinical data
Upside: Lawsuit dismissal (10%)
Legal pressure eases, allowing the company to focus on its clinical pipeline.
- Court grants motion to dismiss based on lack of scienter
What to watch
- September 28, 2026: Deadline for lead plaintiff applications
- FDA regulatory updates regarding Deramiocel
- Capricor Therapeutics quarterly earnings reports for legal reserve updates
Timeline
- — CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit (PR Newswire)
- — CAPR Lawsuit Alert: Capricor Therapeutics Investors Face September 28 Deadline After 64% Stock Drop Tied to Clinical Data Disclosure (PR Newswire)
- — Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel (PR Newswire)
Analysis — what this means
Likely next events
- September 28, 2026: Lead plaintiff application deadline
Sectors affected
- Biotechnology
- Legal Services
- Capital Markets
Regulatory implications
- SEC scrutiny regarding disclosure of clinical data integrity
- Compliance with Securities Exchange Act of 1934 provisions
Historical parallels
- Capricor stock drop of 64% tied to clinical data disclosure (Sept 2026)
Key entities
Sources
- CAPR Deadline: CAPR Investors with Losses in Excess of $100K Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit — PR Newswire
- CAPR Lawsuit Alert: Capricor Therapeutics Investors Face September 28 Deadline After 64% Stock Drop Tied to Clinical Data Disclosure — PR Newswire
- Hagens Berman Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to FDA Review Extension for Deramiocel — PR Newswire
Related cases
- Capricor Therapeutics faces growing legal pressure as investors approach deadline for class action leadership amidst FDA review uncertainties
- Law firm Faruqi & Faruqi calls for lead plaintiffs in Capricor Therapeutics securities class action ahead of September 28 deadline
- Capricor Therapeutics faces a looming lead plaintiff deadline that could shape the outcome of its securities class action lawsuit
- Rosen Law Firm alerts Capricor Therapeutics investors of September 2 lead plaintiff deadline in securities fraud class action
- Capricor Therapeutics faces a class‑action securities lawsuit alleging violations of exchange‑act provisions, triggering potential legal costs and investor scrutiny
- SBS Law invites investors to lead a securities‑fraud class action against Capricor Therapeutics, highlighting a broader pattern of similar shareholder‑rights actions